Advertisement
YOU ARE HERE: LAT HomeCollections

In Brief / PHARMACEUTICALS

Alnylam, Isis form research venture

September 08, 2007|From Times Wire Services

Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc. have formed a venture uniting Nobel Prize winners David Baltimore and Phillip Sharp to create drugs from a newly discovered class of genetic material.

The venture, Regulus Therapeutics, will have exclusive licenses from Alnylam and Isis for technology focused on so-called microRNAs. The molecules regulate networks of genes that may be involved in diseases including cancer, viral infections and metabolic disorders, the companies said.

Advertisement
Los Angeles Times Articles
|
|
|